Posts by: Iqra Mumal

Iqra Mumal

July 10, 2018July 10, 2018

Azithromycin Added to Standard Therapy for P. Aeruginosa Infection Reduces Lung Exacerbations, Trial Finds

cystic fibrosis, News

Adding azithromycin to the standard antibiotic treatment for early Pseudomonas aeruginosa infections is associated with fewer pulmonary exacerbations in children with cystic fibrosis (CF), results from a Phase 3 trial ... Read more

March 1, 2018March 1, 2018

Early Growth Patterns Affect CF Children’s Lung Function at Age 12, Study Shows

cystic fibrosis, News

Children with cystic fibrosis who are able to recover from below-normal growth in their first two years are more likely to achieve normal growth and better lung condition by ... Read more

February 12, 2018February 12, 2018

2 CF Case Reports Show Successful Use of GM-CSF for Treating Nontuberculous Mycobacteria

cystic fibrosis, News

Savara Pharmaceuticals announced the publication of two case reports demonstrating that inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) either eradicated or dramatically reduced Mycobacterium abscessus (M. abscessus) infection, improved clinical outcomes, ... Read more

January 26, 2018January 26, 2018

Humanigen’s Inflammation Therapy Is Only Modestly Effective in CF Patients with an Infection, Trial Shows

cystic fibrosis, News

Humanigen’s anti-inflammatory therapy KB001-A is safe but only modestly effective in cystic fibrosis patients with a Pseudomonas aeruginosa bacteria infection, a Phase 2 clinical trial indicates. In addition to displaying limited ability to ... Read more

January 2, 2018January 2, 2018

Introduction of New Therapies Affects Pregnancy Rates in Women With CF, Study Reports

cystic fibrosis, News

The overall rate at which women with cystic fibrosis are becoming pregnant dropped slightly in recent years — coinciding with the introduction of CFTR modulators and the clinical trials ... Read more

November 6, 2017November 6, 2017

#NACFC2017 – Two Phase 3 Studies of Tezacaftor/Ivacaftor Combo Show Positive Results in CF Patients

cystic fibrosis, News

Vertex Pharmaceuticals, a clinical-stage biopharmaceutical company, recently announced that two Phase 3 studies evaluating its tezacaftor/ivacaftor combination therapy have shown statistically significant and clinically meaningful improvements in lung function in ... Read more

November 3, 2017November 3, 2017

Corbus Pharmaceuticals Receives Anabasum Patent for Inflammatory, Fibrotic Diseases

cystic fibrosis, News

Corbus Pharmaceuticals recently announced that the U.S. Patent and Trademark Office has issued a patent for the use of anabasum, the company’s lead therapy candidate for the treatment of inflammatory ... Read more

November 3, 2017November 3, 2017

#NACFC2017 – Pulmatrix Presenting Preclinical Data on Antifungal Therapy Pulmazole

cystic fibrosis, News

Pulmatrix recently announced that it is presenting positive preclinical data on its antifungal therapy Pulmazole at the North American Cystic Fibrosis Conference (NACFC) (Nov. 2-4, 2017). Pulmazole (PUR1900) is based on itraconazole, ... Read more

October 30, 2017

New 3D Model Lets Researchers Visualize Microbiome in a CF Lung, Study Shows

News

A new tool allows researchers and doctors to visualize a 3D model of a cystic fibrosis (CF) lung that incorporates information about microbes, which may help improve targeted drug ... Read more

September 27, 2017September 27, 2017

Exotect Grant to Target New Therapies for Airway Mucous Secretion in CF, Other Diseases

News

The National Institutes of Health (NIH) has awarded Exotect a $224,576 Small Business Technology Transfer grant to develop small molecule therapies to treat cystic fibrosis and other diseases characterized by excessive airway mucous ... Read more

Pin It on Pinterest